Table 4 Multisystem inflammatory syndrome by organ involvement, management and patient outcomes
From: Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review
Variable | Total (n = 37) |
|---|---|
Adverse Effects by system | |
 CNS | 21 (56.8) |
 CVS | 36 (97.3) |
 GIT | 32 (86.5) |
 Respiratory | 20 (54.1) |
 Skeletal | 16 (43.2) |
 Urinary | 12 (32.4) |
 Endocrine | 0 (0) |
 Reproductive | 0 (0) |
 Circulatory | 25 (67.6) |
 Lymphatic | 12 (32.4) |
 Integumentary | 21 (56.8) |
 Immune | 25 (67.6) |
Laboratory findings | |
 Positive SARS CoV-2 anti nucleoplasmid | 14 (37.8) |
 Positive Anti spike antibodies | 20 (54.1) |
 Positive SARS-CoV-2 antigen | 14 (37.8) |
 Raised acute phase reactants | 33 (88.2) |
Treatment | |
 IVIG | 24 (64.9) |
 Steroids | 30 (81.1) |
 Other treatment | 26 (70.3) |
Outcomes | |
 Survived | 34 (91.9) |
 Hospitalization | 36 (100) |
 Duration (days) | 16.8 (4–90) |
 Admitted to ICU | 14 (37.9) |
 Duration (days) | 6 |
Follow-up duration (days) | 26.5 (0–90) |